People

The People

Centene earns a C+ governance grade: the structural plumbing is investor-friendly (independent chair, fully independent key committees, declassified board, prohibited hedging/pledging, 6x CEO ownership requirement), but pay-for-performance broke down hard in 2025, the only "non-independent" director outside the CEO triggered a related-party flag, and the only meaningful open-market insider buying came at $25–$28 after the stock had already crashed. There is no founder, no controlling shareholder, no skin-in-the-game owner-operator — this is a professionally managed Medicaid utility run on Vanguard/BlackRock/AQR's money.

The People Running This Company

The C-suite is a tight, post-Neidorff team installed in 2021–2022 to clean up the WellCare-era acquisition spree. Sarah London is a 45-year-old technology operator (ex-Optum Ventures, ex-Optum Analytics, Harvard / Booth) — not a lifelong insurance executive. CFO Andrew Asher is the steadier hand, brought in from WellCare via the 2020 acquisition. The general counsel is a former Missouri Attorney General — useful given the company's open SEC matter and PBM settlement history. In April 2026, Centene created two new Group President roles to add operating depth: Daniel Finke (ex-Aetna) for Markets & Commercial, Michael Carson (Wellcare CEO) for Medicare & Specialty.

What They Get Paid

Sarah London earned $19.5M in 2025 — about 80% of it equity. That ranks below the median large-cap US health insurer CEO and is reasonable for a $20B market cap, $195B revenue company. The CEO pay ratio is 206x the median Centene employee ($94,800). The honest test, though, is what the equity actually paid out: London's "Compensation Actually Paid" was only $4.6M in 2025 — less than a quarter of headline pay — because the unvested PSU/RSU stack repriced sharply on the 2025 stock collapse. Pay-for-performance is, mechanically, working.

The 2025 incentive design earns honest credit: the annual bonus payout fell roughly 40% YoY for London (cash incentive $4.3M → $2.1M), and her realized PSU/RSU value collapsed by ~$8.5M as old grants marked down. The 2026 plan ratchets further — the new PSU is now an absolute TSR structure that pays nothing extra above target unless the stock recovers from current levels. That is a more rigorous ask than the typical "relative TSR vs peers" template.

The headline weakness is that base-plus-bonus cash still runs ~$3.6M for the CEO regardless of outcome, and equity grant sizes in 2025 actually went up for the CFO ($7.2M → $13.4M) at the same time the company was losing $6.7B. The Comp Committee's defense is that it had to retain talent through the Marketplace blow-up; the honest read is that grant-size discipline is weaker than vesting discipline.

Are They Aligned?

Ownership. No founder, no insider with 5%+, no controlling shareholder. The top three holders are passive and active institutions: Vanguard 12.4%, BlackRock 7.8%, AQR Capital 6.5%. All directors and officers as a group own about 1.8M shares — under 0.4% of the company.

Insider buying versus selling. The picture is dominated by routine RSU vesting and tax-withholding mechanics, not conviction trades. There were exactly two open-market purchases in the last twelve months — both during the post-July 2025 crash. There were also two open-market sales, both by the same director (Burdick) in early December 2025.

CEO London's $490k purchase at $25.50 was the right symbolic gesture in the panic, but it is small relative to her $13.8M holding and $19.5M annual pay. Director Samuels' $249k buy is the more credible signal — he has no operating exposure to Centene's strategy and put up his own cash. Burdick's $2.6M of selling is awkward optics: it's the only insider doing meaningful selling, and he's the one director the board has formally classified as non-independent because of his LifeStance commercial relationship with Centene.

Capital allocation behavior. Strongly shareholder-friendly on this dimension: 71.6 million shares repurchased Jan 2023 – Dec 2025, $189M of senior notes bought back at par in 2025, and 12 divestitures since 2022 (Magellan businesses, Apixio, Circle Health, Operose, PANTHERx, etc.) cleaning up the Neidorff-era acquisition sprawl. No dividend, no convertible-debt overhangs, no related-party financings. London earns credit for this discipline even with the 2025 operating blow-up.

Related-party. One material item: Centene continues to pay LifeStance Health Group for behavioral-health network services. Director Burdick was LifeStance's Chairman/CEO from Sep 2022 through March 14, 2026. The board notes the contracts pre-date Burdick's LifeStance role and were re-vetted, but it is enough to keep him formally non-independent. One unnamed executive officer also has an immediate family member employed at Centene above the $120k disclosure threshold — disclosed but unnamed, which is mildly less than ideal.

Skin-in-the-game score: 4 / 10. No founder, no insider with material economic exposure, the C-suite collectively owns ~$50M against a $20B market cap. The structure (6x CEO and 7.5x director ownership multiples, plus hedging/pledging bans and a clawback) is best-in-class on paper, but the absolute dollar exposure is too small to call this an owner-operated company. London passed her 6x test only because her base salary is comparatively modest; the CFO and General Counsel are well above their multiples, the COO and CPO are still inside their five-year ramp.

Board Quality

Nine nominees, seven formally independent. The board was substantially refreshed in 2022 after stockholder pressure to declassify, and the median tenure is now 4.2 years. The chair (Eppinger) is the longest-serving director at ~20 years and is independent; the audit committee has a brand-new chair (Tanji, ex-Prudential CFO, appointed Feb 2025) which is healthy refreshment in a company with an active SEC matter and class-action securities litigation outstanding.

The expertise mix is genuinely strong on finance (three former public-company CFOs — Coughlin/Tyco, Tanji/Prudential, plus Blume's CPA/Deloitte background), and on insurance underwriting (Eppinger ran Hanover Insurance and now Stewart). Where it is thin is direct Medicare/Medicaid policy and clinical operations: only London and Burdick have hands-on managed-Medicaid operating experience, and Burdick is non-independent. That gap matters because Centene's 2025 Marketplace blow-up and PBM Medicaid settlements are precisely the failures a clinically-experienced board would have been more likely to challenge sooner. Watch for the next director addition — the board has retained a search firm.

The Verdict

The strongest positives. Independent chair already in place; key committees fully independent; board substantially refreshed since 2022 (now annually elected, not classified); hedging and pledging banned; clawback policy in place; capital allocation has been disciplined (12 divestitures, 71.6M shares retired, debt reduction); 2025 incentive plan actually penalized the CEO when the stock fell — realized pay ($4.6M) was less than a quarter of headline pay ($19.5M), and the 2026 plan tightens further with absolute-TSR PSUs.

The real concerns. Securities class-action lawsuit filed August 2025 over Marketplace-morbidity disclosures, with the SEC matter referenced separately. Over $1B already paid in PBM-related Medicaid settlements across 20+ states — old, but recent enough to inform integrity assessment. The only non-independent outside director (Burdick) is also the one with a related-party LifeStance contract and the only insider doing meaningful open-market selling and the chair of the Quality Committee that should have caught the 2025 miss earlier. Equity grant sizes increased during a $6.7B loss year for the CFO, which sits awkwardly with the comp committee's pay-for-performance narrative. There is no founder or 5%+ insider providing alignment — this company runs on institutional discretion, and Q4 2025 saw the most violent ownership rotation in years (Norges, UBS, Politan all cutting 70%+).

The single thing that would change the grade. Upgrade to B / B+ if (a) Burdick is replaced or recused from the Quality Committee chair, (b) the SEC matter and class action settle without a finding of senior-management knowledge, and (c) 2026 returns to positive adjusted EPS — the existing pay structure would then quietly do its job. Downgrade to C– or lower if the SEC matter expands to fraud allegations, if the related-party LifeStance contract is found to have been mis-priced, or if the board waves through another off-cycle equity grant top-up to retain the CFO/COO before performance has been earned back.